Our computational Software as a Service (SaaS), Platform as a Service (PaaS) and Technology as a Service (TaaS) platform is capable of predicting critical properties of molecules with a high degree of accuracy. This critical capability enables drug discovery teams to design and selectively synthesize molecules with more optimal properties, reducing the average time and costs required to identify a development candidate and increasing the probability that a drug discovery program will enter clinical development.